Experimental drug for Alzheimer’s disease slows decline in thinking
May 03, 2023
Eli Lilly says the drug slows memory and thinking declines in early symptomatic Alzheimer’s disease patients by more than a third.
New Rx instructions tighten use of controversial Alzheimer’s disease drug
Jul 08, 2021
Major changes to prescribing instructions are rare, especially so soon after approval; it change could curb the drug’s use.
Lifestyle intervention can improve cognition, function in early Alzheimer’s disease
Jun 13, 2024
A significant correlation was seen between lifestyle and both cognitive function and Aβ42/40 ratio.
Long-term loneliness tied to risk for memory decline
Aug 08, 2022
The association was particularly strong for those aged 65 years or older and for women.
Changes in movement may indicate preclinical Alzheimer’s disease
Jul 02, 2021
Changes in daytime fractal motor activity regulation may occur in women before cognitive symptoms of Alzheimer’s disease.
Longer reproductive window could up risk for Alzheimer’s disease
Jul 12, 2021
The authors suggest that longer exposure to endogenous estrogen may be associated with increased levels of Alzheimer’s disease biomarkers.
One in three Alzheimer’s, dementia cases tied to modifiable risk factors
May 11, 2022
Risk factors differ based on sex and race and ethnicity.
Family availability impacts formal, informal dementia care
Sep 08, 2021
“The development of a care system that integrates informal with formal care has been considered essential for a sustainable healthcare system, especially one providing dementia care,” the authors...
Second death in trial of experimental Alzheimer’s drug raising concerns
Nov 29, 2022
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.